Citadel Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.82M | Sell |
13,800
-2,200
| -14% | -$292K | ﹤0.01% | 6279 |
|
|
2025
Q4 | $2.27M | Sell |
16,000
-10,300
| -39% | -$1.49M | ﹤0.01% | 5672 |
|
|
2025
Q3 | $3.69M | Buy |
26,300
+5,800
| +28% | +$786K | ﹤0.01% | 4914 |
|
|
2025
Q2 | $2.58M | Buy |
20,500
+1,000
| +5% | +$115K | ﹤0.01% | 5244 |
|
|
2025
Q1 | $2.16M | Sell |
19,500
-33,400
| -63% | -$4.23M | ﹤0.01% | 5385 |
|
|
2024
Q4 | $7.22M | Buy |
52,900
+5,900
| +13% | +$730K | ﹤0.01% | 3399 |
|
|
2024
Q3 | $5.42M | Buy |
47,000
+10,700
| +29% | +$1.47M | ﹤0.01% | 3810 |
|
|
2024
Q2 | $5M | Sell |
36,300
-2,700
| -7% | -$370K | ﹤0.01% | 3753 |
|
|
2024
Q1 | $5.38M | Sell |
39,000
-500
| -1% | -$68.3K | ﹤0.01% | 3841 |
|
|
2023
Q4 | $5.2M | Sell |
39,500
-28,200
| -42% | -$3.25M | ﹤0.01% | 3721 |
|
|
2023
Q3 | $7.62M | Buy |
67,700
+39,700
| +142% | +$4.18M | ﹤0.01% | 3033 |
|
|
2023
Q2 | $2.64M | Buy |
28,000
+3,100
| +12% | +$303K | ﹤0.01% | 4674 |
|
|
2023
Q1 | $2.52M | Sell |
24,900
-22,700
| -48% | -$2.36M | ﹤0.01% | 4941 |
|
|
2022
Q4 | $5.69M | Buy |
47,600
+17,800
| +60% | +$2.08M | ﹤0.01% | 3642 |
|
|
2022
Q3 | $3.17M | Sell |
29,800
-42,200
| -59% | -$4.28M | ﹤0.01% | 4701 |
|
|
2022
Q2 | $7.02M | Buy |
72,000
+18,400
| +34% | +$1.7M | ﹤0.01% | 3200 |
|
|
2022
Q1 | $5.03M | Buy |
53,600
+14,800
| +38% | +$1.25M | ﹤0.01% | 4168 |
|
|
2021
Q4 | $3.31M | Buy |
38,800
+13,900
| +56% | +$1.28M | ﹤0.01% | 5144 |
|
|
2021
Q3 | $2.39M | Sell |
24,900
-41,900
| -63% | -$3.96M | ﹤0.01% | 5913 |
|
|
2021
Q2 | $6.5M | Buy |
66,800
+6,600
| +11% | +$633K | ﹤0.01% | 3892 |
|
|
2021
Q1 | $5.85M | Buy |
60,200
+14,200
| +31% | +$1.49M | ﹤0.01% | 3919 |
|
|
2020
Q4 | $4.41M | Sell |
46,000
-13,200
| -22% | -$1.27M | ﹤0.01% | 3889 |
|
|
2020
Q3 | $5.69M | Sell |
59,200
-57,400
| -49% | -$6.64M | ﹤0.01% | 2971 |
|
|
2020
Q2 | $14.2M | Buy |
116,600
+9,000
| +8% | +$995K | 0.01% | 1832 |
|
|
2020
Q1 | $9.31M | Sell |
107,600
-183,900
| -63% | -$18M | ﹤0.01% | 1928 |
|
|
2019
Q4 | $31.3M | Buy |
291,500
+215,100
| +282% | +$22.5M | 0.01% | 1087 |
|
|
2019
Q3 | $6.88M | Sell |
76,400
-8,000
| -9% | -$747K | ﹤0.01% | 2684 |
|
|
2019
Q2 | $7.13M | Sell |
84,400
-23,300
| -22% | -$1.91M | ﹤0.01% | 2604 |
|
|
2019
Q1 | $9.49M | Sell |
107,700
-129,100
| -55% | -$10.8M | ﹤0.01% | 2152 |
|
|
2018
Q4 | $16.9M | Buy |
236,800
+133,300
| +129% | +$12.8M | 0.01% | 1368 |
|
|
2018
Q3 | $12.7M | Buy |
103,500
+44,900
| +77% | +$5.09M | 0.01% | 1839 |
|
|
2018
Q2 | $5.76M | Buy |
58,600
+12,800
| +28% | +$1.15M | ﹤0.01% | 2569 |
|
|
2018
Q1 | $3.8M | Buy |
45,800
+31,900
| +229% | +$2.69M | ﹤0.01% | 2807 |
|
|
2017
Q4 | $1.08M | Sell |
13,900
-1,400
| -9% | -$95.5K | ﹤0.01% | 4555 |
|
|
2017
Q3 | $938K | Sell |
15,300
-2,000
| -12% | -$106K | ﹤0.01% | 4414 |
|
|
2017
Q2 | $796K | Sell |
17,300
-17,400
| -50% | -$844K | ﹤0.01% | 4430 |
|
|
2017
Q1 | $1.5M | Buy |
34,700
+13,700
| +65% | +$587K | ﹤0.01% | 3422 |
|
|
2016
Q4 | $813K | Buy |
21,000
+6,000
| +40% | +$272K | ﹤0.01% | 4156 |
|
|
2016
Q3 | $760K | Sell |
15,000
-25,600
| -63% | -$1.27M | ﹤0.01% | 4204 |
|
|
2016
Q2 | $1.84M | Sell |
40,600
-18,800
| -32% | -$866K | ﹤0.01% | 2833 |
|
|
2016
Q1 | $2.35M | Buy |
59,400
+3,000
| +5% | +$119K | ﹤0.01% | 2477 |
|
|
2015
Q4 | $3.19M | Sell |
56,400
-19,600
| -26% | -$996K | ﹤0.01% | 2255 |
|
|
2015
Q3 | $3.02M | Buy |
76,000
+1,500
| +2% | +$72.5K | ﹤0.01% | 2455 |
|
|
2015
Q2 | $3.56M | Buy |
74,500
+13,200
| +22% | +$560K | ﹤0.01% | 2399 |
|
|
2015
Q1 | $2.43M | Sell |
61,300
-19,900
| -25% | -$712K | ﹤0.01% | 2826 |
|
|
2014
Q4 | $1.81M | Buy |
81,200
+21,100
| +35% | +$400K | ﹤0.01% | 3026 |
|
|
2014
Q3 | $942K | Buy |
60,100
+32,100
| +115% | +$480K | ﹤0.01% | 3767 |
|
|
2014
Q2 | $416K | Buy |
28,000
+2,300
| +9% | +$32.5K | ﹤0.01% | 4638 |
|
|
2014
Q1 | $414K | Buy |
25,700
+7,700
| +43% | +$132K | ﹤0.01% | 4613 |
|
|
2013
Q4 | $168K | Sell |
18,000
-31,200
| -63% | -$304K | ﹤0.01% | 5195 |
|
|
2013
Q3 | $557K | Buy |
49,200
+29,600
| +151% | +$407K | ﹤0.01% | 3690 |
|
|
2013
Q2 | $262K | Buy |
+19,600
| New | +$241K | ﹤0.01% | 4422 |
|
Other funds holding NBIX
VPM
VCM
Citadel Advisors's NBIX Position: Q1 2026 in Review
Citadel Advisors reduced its Neurocrine Biosciences (NBIX) stake by 27% in Q1 2026, selling an estimated $2.88M and leaving 57,968 shares worth $7.64M. The position accounts for ﹤0.01% of the portfolio, ranked #3660.
Citadel Advisors first reported a position in NBIX in Q2 2013 and has held it in 50 quarters since. The position peaked at $346M in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Citadel Advisors held 57,968 shares of Neurocrine Biosciences worth $7.64M as of Q1 2026.
- Citadel Advisors sold 21,743 Neurocrine Biosciences shares in Q1 2026, an estimated $2.88M.
- Neurocrine Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3660 holding.
- Citadel Advisors first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 50 quarters since.
- Citadel Advisors's Neurocrine Biosciences position peaked at $346M in Q4 2024.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.